Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL198857 | 0.97 | TSHR (0.44) | TSHRFAAHTRPV1THRBDNM1 | |
| SCHEMBL200789 | 0.97 | TSHR (0.44) | TSHRFAAHTRPV1THRBDNM1 | |
| SCHEMBL199780 | 0.97 | TSHR (0.44) | TSHRFAAHTRPV1THRBDNM1 | |
| SCHEMBL201272 | 0.97 | TSHR (0.44) | TSHRFAAHTRPV1THRBDNM1 | |
| SCHEMBL198973 | 0.97 | TSHR (0.44) | TSHRFAAHTRPV1THRBDNM1 | |
| SCHEMBL198894 | 0.97 | TSHR (0.44) | TSHRFAAHTRPV1THRBDNM1 | |
| SCHEMBL201679 | 0.97 | TSHR (0.44) | TSHRFAAHTRPV1THRBDNM1 | |
| SCHEMBL199143 | 0.97 | TSHR (0.44) | TSHRFAAHTRPV1THRBDNM1 | |
| SCHEMBL198438 | 0.97 | TSHR (0.44) | TSHRFAAHTRPV1THRBDNM1 | |
| SCHEMBL201659 | 0.97 | TSHR (0.44) | TSHRFAAHTRPV1THRBDNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158401-A1 | DERIVATIVES OF IMIDAZO[4,5-d]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2024-05-16 | — | — | US | disclosed |
| EP-4288438-A1 | DERIVATIVES OF IMIDAZO[4,5-D]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | Sanofi (FR) | 2023-12-13 | — | — | EP | disclosed |
| WO-2022167438-A1 | DERIVATIVES OF IMIDAZO[4,5-d]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2022-08-11 | — | — | WO | disclosed |
| US-8481736-B2 | Liquid crystalline rylene tetracarboxylic acid derivatives and use thereof | BASF SE (DE) | 2013-07-09 | — | — | US | disclosed |
| US-8088922-B2 | Dibenzorylenetetracarboximides as infrared absorbers | BASF AKTIENGESELLSCHAFT (DE) | 2012-01-03 | — | — | US | disclosed |
| EP-2029573-B1 | DIBENZORYLENETETRACARBOXIMIDES AS INFRARED ABSORBERS | BASF SE (DE) | 2011-10-26 | — | — | EP | disclosed |
| US-20110042651-A1 | LIQUID CRYSTALLINE RYLENE TETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF | BASF SE (DE) | 2011-02-24 | — | — | US | disclosed |
| WO-2010111822-A1 | OLIGOCONDENSED PERYLENE BISIMIDES | BASF SE (DE) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010112452-A1 | OLIGOCONDENSED PERYLENE BISIMIDES | BASF SE (DE) | 2010-10-07 | — | — | WO | disclosed |
| US-20100048904-A1 | DIBENZORYLENETETRACARBOXIMIDES AS INFRARED ABSORBERS | BASF AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | US | disclosed |
| WO-2007138051-A1 | DIBENZORYLENETETRACARBOXIMIDES AS INFRARED ABSORBERS | BASF SE (DE) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007116001-A2 | LIQUID CRYSTALLINE RYLENE TETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF | BASF SE (DE) | 2007-10-18 | — | — | WO | disclosed |
| EP-1843407-A1 | Liquid crystalline rylenetetracarboxylic acid derivatives and their use | BASF AKTIENGESELLSCHAFT (DE) | 2007-10-10 | — | — | EP | disclosed |
| US-4598147-A | THIAZOLE INTERMEDIATES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-07-01 | — | — | US | disclosed |
| EP-0049539-B1 | THIAZOLE DERIVATIVES FOR PREPARING CEPHEM COMPOUNDS AND PROCESSES FOR THEIR PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-10-16 | — | — | EP | disclosed |
| EP-0007633-B1 | CEPHEM COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-04-18 | — | — | EP | disclosed |
| US-4372952-A | Cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-02-08 | — | — | US | disclosed |
| EP-0049539-A1 | Thiazole derivatives for preparing cephem compounds and processes for their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-04-14 | — | — | EP | disclosed |
| US-4284631-A | 7-Substituted cephem compounds and pharmaceutical antibacterial compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-08-18 | — | — | US | disclosed |
| EP-0007633-A2 | Cephem compounds, processes for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048904-A1 | DIBENZORYLENETETRACARBOXIMIDES AS INFRARED ABSORBERS | TDO2, C9, CYP3A43 | TSHR 1062/4885FAAH 586/4885TRPV1 1078/4885 |
| US-20110042651-A1 | LIQUID CRYSTALLINE RYLENE TETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF | TPR, ROR1, CA3 | TSHR 1618/4885FAAH 3869/4885TRPV1 839/4885 |
| US-20240158401-A1 | DERIVATIVES OF IMIDAZO[4,5-d]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | TLR7, TLR8, TLR6 | TSHR 237/4885FAAH 1922/4885TRPV1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.